Bausch Health Companies Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Bausch Health Companies Inc. (BHC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-25.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2015-02-25
- Bausch Health Companies Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2014 was 0.00%.
- Bausch Health Companies Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2013 was 0.00%.
- Bausch Health Companies Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2012 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|
| 2014-12-31 | 0.00% 10-K · filed 2015-02-25 |
| 2013-12-31 | 0.00% 10-K · filed 2015-02-25 |
| 2012-12-31 | 0.00% 10-K · filed 2015-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |